GI
BBIO icon

GAMMA Investing’s BridgeBio Pharma BBIO Stock Holding History

GAMMA Investing’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
1,646
+199
+14% +$13.9K ﹤0.01% 1656
2026
Q1 		$107K Buy
1,447
+29
+2% +$2.1K 0.01% 1615
2025
Q4 		$108K Buy
1,418
+398
+39% +$26.1K 0.01% 1518
2025
Q3 		$53K Buy
1,020
+227
+29% +$11.1K ﹤0.01% 1950
2025
Q2 		$34.2K Sell
793
-127
-14% -$4.62K ﹤0.01% 2161
2025
Q1 		$31.8K Buy
920
+382
+71% +$12.9K ﹤0.01% 2113
2024
Q4 		$14.8K Buy
538
+92
+21% +$2.38K ﹤0.01% 2424
2024
Q3 		$11.4K Buy
446
+67
+18% +$1.76K ﹤0.01% 2402
2024
Q2 		$9.6K Sell
379
-12
-3% -$328 ﹤0.01% 2275
2024
Q1 		$12.1K Buy
391
+76
+24% +$2.58K ﹤0.01% 1955
2023
Q4 		$10.8K Buy
+315
New +$9.46K ﹤0.01% 1863

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

GAMMA Investing's BBIO Position: Q2 2026 in Review

GAMMA Investing increased its BridgeBio Pharma (BBIO) stake by 14% in Q2 2026, buying an estimated $13.9K and bringing the position to 1,646 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

GAMMA Investing first reported a position in BBIO in Q4 2023 and has held it in 11 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • GAMMA Investing held 1,646 shares of BridgeBio Pharma worth $123K as of Q2 2026.
  • GAMMA Investing bought 199 BridgeBio Pharma shares in Q2 2026, an estimated $13.9K.
  • BridgeBio Pharma made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #1656 holding.
  • GAMMA Investing first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 11 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.